Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14

Rhea-AI Filing Summary

Pliant Therapeutics director John T. Curnutte received a grant of stock options covering 70,000 shares of common stock. The options carry an exercise price of $1.14 per share and expire on June 11, 2036, giving him the right to buy shares at that price in the future.

According to the vesting schedule, 25% of the options vest on each of October 1, 2026, January 1, 2027, and April 1, 2027, with the remaining 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting, subject to his continued service as a director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Curnutte John T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 70,000 options Exercise price: $1.14 per share Expiration date: June 11, 2036 +3 more

6 metrics

Option grant size 70,000 options Stock Option (Right to Buy) granted to director John T. Curnutte

Exercise price $1.14 per share Conversion or exercise price of granted stock options

Expiration date June 11, 2036 Option grant expiration for 70,000-share award

First vesting date October 1, 2026 25% of options vest on this date

Second vesting date January 1, 2027 Additional 25% of options vest on this date

Third vesting date April 1, 2027 Another 25% of options vest on this date

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable on October 1, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curnutte John T

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PLIANT THERAPEUTICS (PLRX) disclose about John T. Curnutte on this Form 4?

The company reported that director John T. Curnutte received a grant of stock options for 70,000 shares of common stock at a $1.14 exercise price, expiring June 11, 2036, subject to a multi-date vesting schedule tied to continued board service.

How many PLIANT THERAPEUTICS (PLRX) options were granted to John T. Curnutte?

John T. Curnutte was granted stock options covering 70,000 shares of Pliant Therapeutics common stock. These options give him the right to buy shares at a fixed $1.14 exercise price if and when they vest and he chooses to exercise them before expiration.

What is the exercise price and expiration date of John T. Curnutte’s PLRX stock options?

The options granted to John T. Curnutte have an exercise price of $1.14 per share and an expiration date of June 11, 2036. He may exercise vested options any time before expiration, subject to plan rules and his continued eligibility as a director.

How do the new PLRX stock options for John T. Curnutte vest over time?

The options vest in four equal 25% installments: on October 1, 2026, January 1, 2027, and April 1, 2027, with the final 25% vesting on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual stockholder meeting.

What service conditions apply to John T. Curnutte’s PLRX option grant?

Each vesting installment requires John T. Curnutte to continue serving as a director through the applicable vesting date or, for the final tranche, through the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders.